Matzim La Tablet, Extended Release
FDA Label NDC 52544-695

38 label sections · Submitted to the FDA by Actavis Pharma, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Actavis Pharma, Inc. for the product Matzim La (NDC 52544-695). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 hypertension, 1.2 angina, 2 dosage and administration, 2.1 hypertension, 2.2 angina, 2.3 switching to matzim la (diltiazem hydrochloride) extended-release tablets, 3 dosage forms and strengths, 4 contraindications, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.